Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy

Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy

Direct stimulation of the antitumor activity of immune system through checkpoint inhibitors (ICIs) has demonstrated efficacy in the treatment of different cancer types. The activity of these antibodies takes place in the immunological synapse blocking the binding of the negative immunoregulatory pro...

Full description

Bibliographic Details
Main Authors: M. Xipell, I. Victoria, V. Hoffmann, J. Villarreal, A. García-Herrera, O. Reig, L. Rodas, M. Blasco, E. Poch, B. Mellado, L. F. Quintana
Format: Article
Language:English
Published: Taylor & Francis Group 2018-07-01
Series:OncoImmunology
Subjects:
atezolizumab
immune check-point inhibitors
pd-l1
tubulointerstitial nephritis
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1445952

Internet

http://dx.doi.org/10.1080/2162402X.2018.1445952

Similar Items